Table 4.
No | CAS3 | CD3 | CD20 | CD57 | CD68 | FoxP3 | HLA-DRα | Iba1 | IFNγ | IgG | IL4 | IL10 | Lysozyme | TGFβ | PAX-5 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | +/2 | +/2 | +/3 | –/0 | +/2 | –/0 | +/3 | +/3 | +/2 | +,++/3 | +/3 | +/2 | +/3 | +/2 | +/2 |
2 | +/2 | +/3 | +/3 | +/3 | +/3 | –/0 | +/3 | +/3 | +/3 | +,++/3 | +/3 | +/2 | +/3 | +/2 | +/2 |
3a | ++/2 | +/3 | +/3 | –/0 | ++/2 | +/2 | +,++/3 | +/3 | +,++/2 | +,++/3 | +/3 | +,++/2 | ++,+++/3 | +/2 | +/2 |
4 | +/2 | +/3 | +/3 | –/0 | ++/2 | –/0 | +/3 | +/3 | ++/3 | +/3 | +/3 | +/2 | +/3 | +/2 | +/2 |
5 | +/3 | +/3 | +/3 | –/0 | +/2 | +/2 | +/3 | ++/3 | +/3 | +/2 | +/2 | +,++/2 | ++/3 | +/2 | +/3 |
6 | +/2 | +/2 | +/3 | +/3 | +/3 | –/0 | +/3 | +/2 | +/2 | +/3 | +/2 | +/2 | +/3 | +/2 | +/2 |
7 | +/2 | +/3 | +/3 | +/2 | +/3 | +/2 | +/3 | +/2 | +/3 | +/2 | +/2 | +/2 | +/3 | +/2 | +/2 |
8 | +/2 | +/3 | +/3 | –/0 | +/3 | +/3 | +/2 | +/3 | +/3 | +,++/3 | +/2 | +/2 | +,++/3 | +/2 | +/2 |
9 | ++/3 | ++,+++/3 | +/3 | –/0 | +/3 | +/3 | ++/3 | ++/3 | +/2 | +,++/3 | +,++/2 | +,++/2 | +/3 | +/2 | +/2 |
10 | ++/2 | +/3 | +/3 | –/0 | +/3 | +/3 | +/3 | +/3 | +/2 | +/3 | +/2 | +/2 | ++/3 | +/2 | +/2 |
11b | ++/2 | +/2 | +/3 | –/0 | +/2 | +/2 | +/3 | ++/3 | +/3 | +/3 | +,++/2 | ++,+++/3 | ++,+++/3 | +/2 | +/2 |
12 | +/3 | +/3 | +,++/3 | +/3 | ++/3 | +/3 | +,+++/3 | ++/3 | +/3 | ++/3 | +/3 | +,++/3 | +/3 | +/3 | +/3 |
13c | ++/3 | +/2 | +,++/3 | –/0 | ++/3 | +/2 | +,++/3 | ++/3 | +/3 | +/3 | +/3 | ++,+++/3 | ++,+++/3 | ++/2 | |
14 | ++/3 | +/2 | +/2 | –/0 | +/3 | +/2 | +/3 | +,++/3 | +/3 | +/2 | +/2 | +/3 | +/3 | +/2 | +/2 |
15 | +/3 | +/3 | +,++/3 | +/3 | +/3 | +/3 | ++/3 | +,++/3 | +,++/3 | +,++/3 | +/3 | ++,+++/3 | ++/2 | +/2 | +/3 |
16 | ++/3 | ++/3 | +/3 | –/0 | +/3 | +/2 | +/3 | +,++/3 | +/3 | +/2 | +/2 | +/2 | +/3 | +/2 | +/3 |
17 | ++/3 | ++/3 | ++/3 | +/2 | +/3 | +/3 | +,++/3 | +,++/3 | +,++/3 | +/3 | +/3 | +,++/2 | +,++/2 | +/3 | +/2 |
18 | ++/3 | ++/3 | ++/3 | +/3 | ++/3 | +/3 | ++,+++/3 | ++/3 | +/3 | ++/3 | +/2 | +,++/3 | ++/3 | +/2 | +,++/3 |
19 | +++/3 | ++/3 | +,++/2 | +/2 | +/2 | +/3 | +,++/3 | ++++/3 | +++/3 | ++/3 | +,++/3 | ++,+++/2 | +,++/3 | +/3 | +/2 |
20 | +/3 | +/2 | +/3 | –/0 | +/2 | +/3 | +/3 | +,++/3 | +/3 | +/3 | +/3 | +/3 | +,++/3 | –/0 | +/2 |
21 | +/3 | +/3 | +/3 | +/2 | +/2 | +/2 | +/3 | +/3 | +/3 | +/3 | +/2 | +/3 | +,++/3 | +/2 | +/2 |
22 | ++/3 | +,++/3 | +/3 | +/2 | +/2 | +/2 | +,+++/3 | +/3 | +/2 | +/2 | +,++/2 | +/2 | +/3 | +/2 | +/3 |
23 | +/2 | +/3 | +/3 | +/2 | +/3 | +/2 | +,++/3 | +/3 | +,++/3 | +/3 | +/2 | +/3 | +/3 | +/2 | +/2 |
24 | +/3 | +/3 | +/3 | –/0 | +/3 | +/2 | +/3 | +/3 | +/2 | +/3 | +/3 | +/3 | +/3 | +/2 | +/2 |
25d | ++/3 | ++++/3 | ++,+++/3 | +/3 | ++,+++/3 | +/3 | +,++/3 | +/3 | +/3 | +,++/3 | ++,+++/2 | +/3 | ++,+++/3 | +/2 | +,++/3 |
26 | +/3 | +/3 | +/3 | NE | NE | NE | NE | +/3 | +/3 | +/3 | NE | NE | NE | NE | NE |
27e | +/3 | +/2 | +/3 | –/0 | +,++/3 | +/2 | +/2 | +/2 | +/2 | +/3 | +/2 | +/2 | +,++/3 | +/2 | +/2 |
28 | +/3 | +/3 | +/3 | –/0 | –/0 | –/0 | +/3 | +/3 | –/0 | –/0 | +/2 | +/2 | –/0 | –/0 | +/3 |
29 | +/3 | +/3 | +/3 | –/0 | –/0 | –/0 | +/3 | +/3 | +/3 | +/2 | +/2 | +,++/2 | –/0 | +/3 | +/3 |
30 | +/3 | +/3 | +/3 | –/0 | –/0 | –/0 | +/3 | +/3 | –/0 | +/2 | +/2 | +/2 | +/2 | +/2 | +/3 |
CD, cluster of differentiation; FoxP3, Forkhead Box P3; HLA, human leukocyte antigen (synonym major histocompatibility complex); IFN, interferon; Ig, immunoglobulin; IL, interleukin; TGF, transforming growth factor; Pax-5, paired box 5; NE, not evaluated. Semiquantitative analysis of immunopositive cells: –, no; +, <10%; ++, 10–50%; +++, 50–90%, and ++++, >90% immunopositive cells. Subjective labeling intensity score of immunopositive cells: 0, 1, 2, and 3.
Multisystemic hyphate mycosis (lung, kidney).
Hyphate mycosis (lung).
Suspect Brucella coinfection (primarily CNS lesions).
Sepsis by Staphylococcus aureus (particularly severe CNS and lung lesions).
Multisystemic hyphate mycosis (lung, cerebrum).